A randomised, placebo-controlled trial of glycopyrrolate for the treatment of noisy respiratory secretions at the end of life-A pilot study
Dr Caitlin Sheehan
24 participants
Jun 1, 2011
Interventional
Conditions
Summary
This study looks at the effect of a drug, called Glycopyrrolate, on noisy rattling breathing in palliative care patients at the end of life. Who is it for? You can join this study if you are an inpatient in a Palliative Care unit and are willing to discuss end of life care. Trial details Participants will be randomly divided into one of two groups. One group will receive a drug called Glycopyrrolate. This is administered via an injection followed by a continuous infusion (into the vein) for a duration of 24 hours . The other group will receive a placebo (sham) treatment also delivered in the same manner. The placebo has no expected treatment effect. Participants will not know which group they have been allocated to. This study aims to determine whether a larger scale trial of the drug, Glycopyrrolate, is feasible for the treatment of noisy rattling breathing at the end of life.
Eligibility
Inclusion Criteria5
- Age > 18 years
- Life-limiting illness (malignant or non-malignant)
- Inpatient in a Palliative Care unit
- Able to provide informed consent prior to entering the terminal phase
- Willing to discuss end of life care.
Exclusion Criteria4
- Documented hypersensitivity to glycopyrrolate.
- Glaucoma
- Pregnant or Breastfeeding
- Estimated glomerular filtration rate (eGFR) < 25 ml/min
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Glycopyrrolate 0.4mg initial subcutaneous dose immediately followed by continuous subcutaneous infusion of 1.2mg/24hours ( 0.05mg/hr) for a total of 24 hours.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611000484943